Andrx, Amphastar Pen Deal For Generic Lovenox
Amphastar's generic version is currently the subject of a patent infringement lawsuit brought by Aventis and is under a 30-month stay that expires in February 2006.
In December, Aventis’ bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally won approval from the U.S. Patent and Trademark office.
The USPTO previously rejected two attempts...
To view the full article, register now.